From the Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, Toronto, Ontario, Canada.
K. Tselios, MD, PhD; D.D. Gladman, MD, FRCPC; J. Su, MB, MSc; M.B. Urowitz, MD, FRCPC, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network.
J Rheumatol. 2020 Sep 1;47(9):1366-1373. doi: 10.3899/jrheum.191064. Epub 2020 Apr 1.
Advanced chronic kidney disease (CKD) carries an increased risk for progression to endstage renal disease (ESRD). We aimed to determine the rate of progression and the factors that drive the decline of renal function in lupus nephritis (LN).
Patients with advanced LN-related CKD were identified from our longterm longitudinal cohort. Advanced CKD was defined as stage 3b [estimated glomerular filtration rate (eGFR) = 30-44 ml/min/1.73 m] and stage 4 (eGFR = 15-29 ml/min/1.73 m). All individuals were followed until progression to ESRD or the last visit and were divided into "progressors" and "non- progressors." Demographic, clinical, immunological, and therapeutic variables were compared at baseline. Multivariable Cox regression analysis (both time-dependent and independent) was performed to identify predictors for progression.
One hundred eighteen patients (74 CKD 3b and 44 CKD 4) were included. Forty-five patients progressed (29 to ESRD and 16 from CKD 3b to CKD 4) after 6 years on average. No significant decline in the renal function was observed in 73 patients ("non-progressors") after 10 years on average. Active serology (high anti-dsDNA titers and low complements C3/C4) at the time of CKD diagnosis and any increase of the daily prednisone dose after baseline were strongly associated with progression. Treatment with renin angiotensin system (RAS) blockers was associated with less risk for progression.
Dialysis is not inevitable in LN-related advanced CKD because 62% of our patients did not progress over 10 years of followup on average. Certain predictors were identified to affect progression to ESRD.
晚期慢性肾脏病(CKD)会增加进展为终末期肾病(ESRD)的风险。我们旨在确定狼疮性肾炎(LN)患者肾功能下降的进展速度和驱动因素。
从我们的长期纵向队列中确定患有晚期 LN 相关 CKD 的患者。晚期 CKD 定义为 3b 期[eGFR=30-44ml/min/1.73m]和 4 期[eGFR=15-29ml/min/1.73m]。所有患者均随访至进展为 ESRD 或最后一次就诊,并分为“进展者”和“非进展者”。比较基线时的人口统计学、临床、免疫和治疗变量。进行多变量 Cox 回归分析(时间依赖和独立)以确定进展的预测因素。
共纳入 118 例患者(74 例 CKD 3b 和 44 例 CKD 4)。平均 6 年后,45 例患者进展(29 例进展为 ESRD,16 例从 CKD 3b 进展为 CKD 4)。平均 10 年后,73 例患者(“非进展者”)肾功能未见明显下降。CKD 诊断时的活跃血清学(高抗 dsDNA 滴度和低补体 C3/C4)和基线后每日泼尼松剂量的任何增加均与进展密切相关。使用肾素血管紧张素系统(RAS)阻滞剂治疗与进展风险降低相关。
LN 相关晚期 CKD 患者并非必然需要透析,因为我们的患者中有 62%在平均 10 年的随访中没有进展。确定了某些预测因素会影响进展为 ESRD。